Physician profile
Morgan H Lyons
NPI 1154418176
$7,252.95
in general payments reported to CMS, 2019-2025
30 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $393 · 2021: $813 · 2022: $449 · 2023: $1,292 · 2024: $1,296 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,827 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,185.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,043.27 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,040.87 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $720.61 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $441.51 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $277.60 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $273.49 | 2019-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $222.37 | 2019-2024 | Evkeeza |
| Abbott Laboratories | $220.39 | 2019-2025 | Cardiomems |
| Boston Scientific Corporation | $206.21 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Bodyguardian, Latitude Communicator Power Supply |
| Pfizer INC. | $194.49 | 2019-2025 | |
| Esperion Therapeutics, INC. | $187.31 | 2021-2025 | Nexletol |
| Philips North America LLC | $184.68 | 2020-2025 | (Ck4) Mcot, Diagnostic Ecg Service, Ecc Solutions |
| Amarin Pharma, INC. | $158.91 | 2019-2020 | |
| Recor Medical INC | $128.05 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $108.64 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $101.98 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $89.57 | 2019-2024 | |
| Gilead Sciences, INC. | $85.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.04 | 2025 | |
| Novo Nordisk INC | $57.61 | 2023-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.47 | 2019-2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $35.19 | 2023 | Crosser Iq |
| Heartflow, INC. | $30.63 | 2025 | |
| Agiliti Health, INC. | $28.92 | 2023 | Big Turn Mattress Family, Rotate Mattress Family |
| Lundbeck LLC | $24.29 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.13 | 2024 | Edarbi |
| Kestra Medical Technology Services, INC. | $19.78 | 2025 | Assure Wcd |
| Terumo Medical Corporation | $19.10 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $11.62 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.